FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

_	Check this box if no longer subject to Section 16.
1 1	Form 4 or Form 5 obligations may continue. See
$\overline{}$	Instruction 1/h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person* <u>Ciarico Domenico</u>					2. Issuer Name and Ticker or Trading Symbol Endo International plc [ENDP]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ENDO INTERNATIONAL PLC FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD					3. Date of Earliest Transaction (Month/Day/Year) 09/03/2020									X Officer (give title below) Other (specify below) EVP & Chief Commercial Officer					
(Street) BALLSBRIDGE, DUBLIN L2					If Amendment, Date of Original Filed (Month/Day/Year)							6. Individ	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip																	
										7. Nature of Indirect									
				(Mon	th/Day/Year	Execution Date, if any (Month/Day/Year)		Code (Ins	v V	Amount	(A) or (D)		Price	Beneficially Own Following Repor Transaction(s) (I and 4)	ted Indirect (I)		l) (Instr. 4)	Beneficial Ownership (Instr. 4)	
Ordinary Shares	Ordinary Shares			09/0	03/2020(1	(1)		F		19,18	87 ⁽²⁾ D \$		\$2.91(3)	55,958		D			
			Table I							sed of, o			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	eise (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code (In	istr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		е	7. Title and Amount of Se Underlying Derivative Se 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following	ve Own es Forn ally (D) o	ect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Explanation of Response	Security			Code	V (A) (D)			Date Exercisa		Expiration Nu			Amount or Number of Shares		Reporte Transac (Instr. 4)	d tion(s)	r. 4)		

- 1. Thirty-three and one-third percent (33 1/3%) of Mr. Ciarico's September 3, 2019 grant of restricted stock units (RSUs) vested on September 3, 2020.

 2. These shares represent stock withheld by Endo International plc to satisfy Mr. Ciarico's tax withholding obligations on shares acquired upon vesting of RSUs.
- 3. Represents the vesting price which is the average of the high and low share price on September 3, 2020.

Remarks:

/s/ Matthew J. Maletta, by power of

09/08/2020

<u>attorney</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\mbox{^{\ast}}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Matthew J. Maletta, Yoon Ah Oh, Carrie A. Nichol, Ju

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of 1
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's secur:
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned acknowledges that:
- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirer
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing to the source of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signed

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1 day of August 2019.

SIGNATURE TITLE

/S/ DOMENICO CIARICO NAME: Domenico Ciarico Executive Vice President and Chief Commercial

Officer, Sterile & Generics

STATE OF New York: COUNTY OF Rockland:

On this 1 day of August 2019, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instru IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/S/ MARGARET MINCHIN Notary Public

MARGARET MINCHIN NOTARY PUBLIC, STATE OF NEW YORK Registration No. 01MI5012405 Qualified in Orange County Commission Expires June 15, 2023